LUMEXA IMAGING HOLDINGS INC (LMRI) Stock Fundamental Analysis

NASDAQ:LMRI • US5502491062

14.55 USD
-0.43 (-2.87%)
At close: Feb 20, 2026
14.55 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, LMRI scores 1 out of 10 in our fundamental rating. LMRI was compared to 102 industry peers in the Health Care Providers & Services industry. LMRI may be in some trouble as it scores bad on both profitability and health. LMRI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year LMRI has reported negative net income.
  • In the past year LMRI had a positive cash flow from operations.
LMRI Yearly Net Income VS EBIT VS OCF VS FCFLMRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 -50M -100M

1.2 Ratios

  • LMRI's Return On Assets of -5.57% is on the low side compared to the rest of the industry. LMRI is outperformed by 67.65% of its industry peers.
  • LMRI has a Return On Equity of -56.31%. This is in the lower half of the industry: LMRI underperforms 72.55% of its industry peers.
Industry RankSector Rank
ROA -5.57%
ROE -56.31%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMRI Yearly ROA, ROE, ROICLMRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 -20 -40 -60

1.3 Margins

  • With a Gross Margin value of 10.14%, LMRI is not doing good in the industry: 75.49% of the companies in the same industry are doing better.
  • LMRI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMRI Yearly Profit, Operating, Gross MarginsLMRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 0 5 -5 10 -10

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • LMRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LMRI has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, LMRI has a worse debt to assets ratio.
LMRI Yearly Shares OutstandingLMRI Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 20M 40M 60M 80M
LMRI Yearly Total Debt VS Total AssetsLMRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 500M 1B 1.5B

2.2 Solvency

  • LMRI has an Altman-Z score of 0.58. This is a bad value and indicates that LMRI is not financially healthy and even has some risk of bankruptcy.
  • LMRI's Altman-Z score of 0.58 is on the low side compared to the rest of the industry. LMRI is outperformed by 73.53% of its industry peers.
  • LMRI has a debt to FCF ratio of 6731.19. This is a negative value and a sign of low solvency as LMRI would need 6731.19 years to pay back of all of its debts.
  • LMRI has a Debt to FCF ratio of 6731.19. This is in the lower half of the industry: LMRI underperforms 63.73% of its industry peers.
  • A Debt/Equity ratio of 7.19 is on the high side and indicates that LMRI has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 7.19, LMRI is doing worse than 79.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 7.19
Debt/FCF 6731.19
Altman-Z 0.58
ROIC/WACCN/A
WACC10.01%
LMRI Yearly LT Debt VS Equity VS FCFLMRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 0.92 indicates that LMRI may have some problems paying its short term obligations.
  • The Current ratio of LMRI (0.92) is worse than 74.51% of its industry peers.
  • A Quick Ratio of 0.92 indicates that LMRI may have some problems paying its short term obligations.
  • LMRI has a worse Quick ratio (0.92) than 69.61% of its industry peers.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.92
LMRI Yearly Current Assets VS Current LiabilitesLMRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • LMRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.01%, which is quite impressive.
  • Looking at the last year, LMRI shows a small growth in Revenue. The Revenue has grown by 1.38% in the last year.
EPS 1Y (TTM)23.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
Revenue 1Y (TTM)1.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.78%

3.2 Future

  • LMRI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.04% yearly.
  • The Revenue is expected to grow by 6.65% on average over the next years.
EPS Next Y101.44%
EPS Next 2Y67.47%
EPS Next 3Y45.04%
EPS Next 5YN/A
Revenue Next Year9.29%
Revenue Next 2Y7.13%
Revenue Next 3Y6.65%
Revenue Next 5YN/A

3.3 Evolution

LMRI Yearly Revenue VS EstimatesLMRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
LMRI Yearly EPS VS EstimatesLMRI Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LMRI. In the last year negative earnings were reported.
  • LMRI is valuated rather expensively with a Price/Forward Earnings ratio of 18.17.
  • Based on the Price/Forward Earnings ratio, LMRI is valued a bit cheaper than the industry average as 63.73% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.06. LMRI is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 18.17
LMRI Price Earnings VS Forward Price EarningsLMRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, LMRI is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
  • LMRI's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. LMRI is more expensive than 62.75% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7519.11
EV/EBITDA 122.96
LMRI Per share dataLMRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • LMRI's earnings are expected to grow with 45.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.47%
EPS Next 3Y45.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LMRI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LUMEXA IMAGING HOLDINGS INC

NASDAQ:LMRI (2/20/2026, 8:00:01 PM)

After market: 14.55 0 (0%)

14.55

-0.43 (-2.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.6%
Ins Owner Change85.2%
Market Cap1.38B
Revenue(TTM)948.87M
Net Income(TTM)-94.10M
Analysts83.33
Price Target23.05 (58.42%)
Short Float %1.45%
Short Ratio1.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 18.17
P/S 1.45
P/FCF 7519.11
P/OCF 54.43
P/B 8.23
P/tB N/A
EV/EBITDA 122.96
EPS(TTM)-1
EYN/A
EPS(NY)0.8
Fwd EY5.5%
FCF(TTM)0
FCFY0.01%
OCF(TTM)0.27
OCFY1.84%
SpS10.03
BVpS1.77
TBVpS-7.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.57%
ROE -56.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.15%
FCFM 0.02%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 7.19
Debt/FCF 6731.19
Debt/EBITDA 55.8
Cap/Depr 66.4%
Cap/Sales 2.65%
Interest Coverage N/A
Cash Conversion 117.38%
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.92
Altman-Z 0.58
F-ScoreN/A
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.33%
EPS Next Y101.44%
EPS Next 2Y67.47%
EPS Next 3Y45.04%
EPS Next 5YN/A
Revenue 1Y (TTM)1.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.78%
Revenue Next Year9.29%
Revenue Next 2Y7.13%
Revenue Next 3Y6.65%
Revenue Next 5YN/A
EBIT growth 1Y-26.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1534.51%
EBIT Next 3Y162.45%
EBIT Next 5YN/A
FCF growth 1Y-4.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.56%
OCF growth 3YN/A
OCF growth 5YN/A

LUMEXA IMAGING HOLDINGS INC / LMRI FAQ

What is the fundamental rating for LMRI stock?

ChartMill assigns a fundamental rating of 1 / 10 to LMRI.


What is the valuation status for LMRI stock?

ChartMill assigns a valuation rating of 3 / 10 to LUMEXA IMAGING HOLDINGS INC (LMRI). This can be considered as Overvalued.


Can you provide the profitability details for LUMEXA IMAGING HOLDINGS INC?

LUMEXA IMAGING HOLDINGS INC (LMRI) has a profitability rating of 0 / 10.


Can you provide the financial health for LMRI stock?

The financial health rating of LUMEXA IMAGING HOLDINGS INC (LMRI) is 0 / 10.